
<HTML>
<HEAD>
<TITLE>Exhibit 99.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<P align="right" style="font-size: 10pt"><B>EXHIBIT 99.1</B>



<P align="left" style="font-size: 10pt"><B>Company Press Release</B><BR>
<I>SOURCE: DATATRAK International, Inc.</I>


<P align="center" style="font-size: 10pt"><B>DATATRAK INTERNATIONAL PRICES<BR>
PRIVATE PLACEMENT</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CLEVELAND, Ohio, December&nbsp;24, 2004 &#151; DATATRAK International, Inc. (Nasdaq: DATA), the
leading and most experienced Application Service Provider (&#147;ASP&#148;) in the Electronic Data Capture
(&#147;EDC&#148;) industry, today announced that it has agreed to the terms of a private placement financing
with a group of institutional investors in the aggregate principal amount of approximately $4.6
million.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The financing will consist of the sale of 486,313 Common Shares at a price of $9.50
per share and will include the issuance to the investors of warrants to purchase a total of 72,948
Common Shares at an exercise price of $14.40 and with an expiration date of December&nbsp;23, 2007.
Warrants to purchase an additional 21,316 Common Shares will be granted to a placement agent who
assisted the Company in the private placement. Net proceeds to the Company are anticipated to be
approximately $4.4&nbsp;million. In connection with the agreement executed by the parties, the Company
will grant registration rights for purchased Common Shares and the Common Shares issuable upon
exercise of the warrants. Closing of this private placement is dependent upon the satisfaction of
customary terms and conditions.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The securities offered in the private placement have not been registered under the Securities
Act of 1933 or any state securities laws, and unless so registered may not be offered or sold in
the United States, except pursuant to an exemption from, or in a transaction subject to, the
registration requirements of the Securities Act of 1933 and applicable state securities laws. This
press release does not constitute an offer to sell, or the solicitation of an offer to buy, nor
shall there be any sale of the Common Shares or Warrants in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or qualification under the securities
laws of any such jurisdiction.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;About DATATRAK International


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;DATATRAK International, Inc. is a worldwide ASP for the EDC industry. The Company provides a
suite of software products supporting the use of DATATRAK EDC&#174; and related services to the
pharmaceutical, biotechnology, and medical device industries. DATATRAK EDC&#174; was developed in order
to deliver clinical research data from investigative sites to clinical trial sponsors faster and
more efficiently than conventional, manual methods. DATATRAK EDC&#174; can be deployed worldwide in
either a distributed platform using laptop computers or in a centralized environment using the
Internet. DATATRAK EDC&#174; software and its earlier versions have successfully supported many
international clinical studies involving thousands of clinical research sites and encompassing tens
of thousands of patients in over 46 countries. DATATRAK International, Inc.&#146;s product suite has
been utilized in some aspect of the clinical development of 14 separate drugs that have received
regulatory approval from either the United States Food and Drug Administration or counterpart
European bodies. DATATRAK International, Inc. has offices located in Cleveland, Ohio and Bonn,
Germany. Its common stock is listed on the Nasdaq Stock Market under the symbol &#147;DATA.&#148; Visit
the DATATRAK International, Inc. web site at <U>www.datatrak.net</U> or <U>www.datatraknet.de.</U>


<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except for the historical information contained in this press release, the statements
made in this release are forward-looking statements. Factors that may cause actual results to
differ materially from those in the forward-looking statements include the ability of the Company
to absorb corporate overhead and other fixed costs in order to successfully market the DATATRAK
EDC<FONT style="font-family: Symbol">&#212;</FONT> software; the development and fluctuations in the market for EDC technology; continued
unreliability of the Internet infrastructure; the degree of the Company&#146;s success in obtaining new
contracts; the timing of payments from customers and the timing of clinical trial sponsor decisions
to conduct new clinical trials or cancel or delay ongoing trials; dependence on key personnel;
governmental regulation; the early stage of the Company&#146;s EDC business and operations; and general
economic conditions. In addition, the Company&#146;s success depends on the outcome of various strategic
initiatives it has undertaken, all of which are based on assumptions made by the Company concerning
trends in the clinical research market and the health care industry<B>.</B>


<P align="left" style="font-size: 10pt">CONTACTS:

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="48%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="48%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Jeffrey A. Green, Pharm.D., FCP
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Terry C. Black</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">President and Chief Executive Officer
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Chief Financial Officer</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">DATATRAK International, Inc.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">DATATRAK International, Inc.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">440/443-0082 x112
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">440/443-0082 x110</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="left" style="font-size: 10pt">Neal Feagans<BR>
Investor Relations<BR>
Feagans Consulting, Inc.<BR>
303-449-1184



<P align="center" style="font-size: 10pt">&nbsp;
</DIV>


</BODY>
</HTML>

